Literature DB >> 31804858

Systematic Review of the Cost Effectiveness of Breast Cancer Prevention, Screening, and Treatment Interventions.

Jinani Jayasekera1, Jeanne S Mandelblatt1.   

Abstract

Entities:  

Mesh：

Year:  2019        PMID： 31804858      PMCID： PMC6994253          DOI： 10.1200/JCO.19.01525

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  88 in total

1.  Early stage cost-effectiveness analysis of a BRCA1-like test to detect triple negative breast cancers responsive to high dose alkylating chemotherapy.

Authors:  Anna Miquel-Cases; Lotte M G Steuten; Valesca P Retèl; Wim H van Harten
Journal:  Breast       Date:  2015-04-28       Impact factor: 4.380

2.  Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada.

Authors:  C L Attard; A N Pepper; S T Brown; M F Thompson; P-O Thuresson; S Yunger; S Dent; A H Paterson; G A Wells
Journal:  J Med Econ       Date:  2014-11-10       Impact factor: 2.448

3.  An updated systematic review of the cost-effectiveness of therapies for metastatic breast cancer.

Authors:  Anagha Gogate; Jason S Rotter; Justin G Trogdon; Ke Meng; Christopher D Baggett; Katherine E Reeder-Hayes; Stephanie B Wheeler
Journal:  Breast Cancer Res Treat       Date:  2019-01-02       Impact factor: 4.872

4.  Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer.

Authors:  Quang A Le; Yuna H Bae; Jenny H Kang
Journal:  Breast Cancer Res Treat       Date:  2016-08-29       Impact factor: 4.872

5.  Cost Effectiveness of the Oncotype DX DCIS Score for Guiding Treatment of Patients With Ductal Carcinoma In Situ.

Authors:  Ann C Raldow; David Sher; Aileen B Chen; Abram Recht; Rinaa S Punglia
Journal:  J Clin Oncol       Date:  2016-09-30       Impact factor: 44.544

6.  Mammographic screening in BRCA1 mutation carriers postponed until age 40: Evaluation of benefits, costs and radiation risks using models.

Authors:  Inge-Marie Obdeijn; Eveline A M Heijnsdijk; M G Myriam Hunink; Madeleine M A Tilanus-Linthorst; Harry J de Koning
Journal:  Eur J Cancer       Date:  2016-06-15       Impact factor: 9.162

Review 7.  Systematic Review of the Cost Effectiveness of Breast Cancer Prevention, Screening, and Treatment Interventions.

Authors:  Jinani Jayasekera; Jeanne S Mandelblatt
Journal:  J Clin Oncol       Date:  2019-12-05       Impact factor: 44.544

8.  Cost-effectiveness of palbociclib in hormone receptor-positive advanced breast cancer.

Authors:  H Mamiya; R K Tahara; S M Tolaney; N K Choudhry; M Najafzadeh
Journal:  Ann Oncol       Date:  2017-08-01       Impact factor: 32.976

9.  Economic Evaluation of Fulvestrant 500 mg Compared to Generic Aromatase Inhibitors in Patients with Advanced Breast Cancer in Sweden.

Authors:  Ugne Sabale; Mattias Ekman; Daniel Thunström; Claire Telford; Christopher Livings
Journal:  Pharmacoecon Open       Date:  2017-12

Review 10.  Comparative Cost-Effectiveness of Drugs in Early versus Late Stages of Cancer; Review of the Literature and a Case Study in Breast Cancer.

Authors:  Evgeni Dvortsin; Judith Gout-Zwart; Ernst-Lodewijk Marie Eijssen; Jan van Brussel; Maarten J Postma
Journal:  PLoS One       Date:  2016-01-22       Impact factor: 3.240
View more
  7 in total

1.  Weighing Costs and Benefits in the Economics of Cancer Care.

Authors:  Scott D Ramsey; Stacie B Dusetzina
Journal:  J Clin Oncol       Date:  2019-12-05       Impact factor: 44.544

Review 2.  Systematic Review of the Cost Effectiveness of Breast Cancer Prevention, Screening, and Treatment Interventions.

Authors:  Jinani Jayasekera; Jeanne S Mandelblatt
Journal:  J Clin Oncol       Date:  2019-12-05       Impact factor: 44.544

3.  Adherence to guidance for prioritizing higher risk groups for breast cancer screening during the COVID-19 pandemic in the Ontario Breast Screening Program: a descriptive study.

Authors:  Anna M Chiarelli; Meghan J Walker; Gabriela Espino-Hernandez; Natasha Gray; Ayesha Salleh; Chamila Adhihetty; Julia Gao; Samantha Fienberg; Michelle A Rey; Linda Rabeneck
Journal:  CMAJ Open       Date:  2021-12-21

4.  Cost-Effectiveness Analysis of Imaging Modalities for Breast Cancer Surveillance Among BRCA1/2 Mutation Carriers: A Systematic Review.

Authors:  Jiaxin Li; Ziqi Jia; Menglu Zhang; Gang Liu; Zeyu Xing; Xin Wang; Xin Huang; Kexin Feng; Jiang Wu; Wenyan Wang; Jie Wang; Jiaqi Liu; Xiang Wang
Journal:  Front Oncol       Date:  2022-01-10       Impact factor: 6.244

Review 5.  Uptake Rates of Risk-Reducing Surgeries for Women at Increased Risk of Hereditary Breast and Ovarian Cancer Applied to Cost-Effectiveness Analyses: A Scoping Systematic Review.

Authors:  Julia Simões Corrêa Galendi; Sibylle Kautz-Freimuth; Stephanie Stock; Dirk Müller
Journal:  Cancers (Basel)       Date:  2022-03-31       Impact factor: 6.639

6.  Costs and Effects of Implementing Digital Tomosynthesis in a Population-Based Breast Cancer Screening Program: Predictions Using Results from the To-Be Trial in Norway.

Authors:  Tron Anders Moger; Åsne Holen; Berit Hanestad; Solveig Hofvind
Journal:  Pharmacoecon Open       Date:  2022-07-07

7.  Cost-effectiveness of palbociclib in early breast cancer patients with a high risk of relapse: Results from the PENELOPE-B trial.

Authors:  Katya Galactionova; Sibylle Loibl; Paola Salari; Frederik Marmé; Miguel Martin; Michael Untch; Hervé R Bonnefoi; Sung-Bae Kim; Harry D Bear; Nicole McCarthy; Karen A Gelmon; José A García-Sáenz; Catherine M Kelly; Toralf Reimer; Masakazu Toi; Hope S Rugo; Michael Gnant; Andreas Makris; Nicole Burchardi; Matthias Schwenkglenks
Journal:  Front Oncol       Date:  2022-09-05       Impact factor: 5.738
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.